Low doses of bromocriptine shorten the interestrous interval in the bitch without lowering plasma prolactin concentration

Beijerink, Niek; Dieleman, S.J.; Kooistra, Hans S.; Okkens, A.C.

doi:10.1016/s0093-691x(03)00170-5

Cited by 27 publications

(18 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In-line with observations in boars, in which bromocryptine-induced hypoprolactinemia did not alter LH secretion patterns [30], the cabergoline-induced prolactin suppression in our dogs had no effect on the secretion patterns of LH. In the bitch it has been demonstrated that shortening of the interoestrous interval by the dopamine agonist bromocryptine is due to a direct stimulating effect of dopamine on GnRH secretion and a subsequent gonadotrophin release [44]. From the results of the present study, a corresponding effect could not be verified.…”

Section: Discussioncontrasting

confidence: 82%

Effects of the dopamine agonist cabergoline on the pulsatile and TRH-induced secretion of prolactin, LH, and testosterone in male beagle dogs

Koch

Hoppen²,

Dieleman

et al. 2006

Theriogenology

Self Cite

View full text Add to dashboard Cite

In the present study, the pulsatile serum profiles of prolactin, LH and testosterone were investigated in eight clinically healthy fertile male beagles of one to six years of age. Serum hormone concentrations were determined in blood samples collected at 15 min intervals over a period of 6 h before (control) and six days before the end of a four weeks treatment with the dopamine agonist cabergoline (5 mg kg À1 bodyweight/day). In addition, the effect of cabergoline administration was investigated on thyrotropin-releasing hormone (TRH)-induced changes in the serum concentrations of these hormones.In all eight dogs, the serum prolactin concentrations (mean 3.0 AE 0.3 ng ml À1 ) were on a relatively constant level not showing any pulsatility, while the secretion patterns of LH and testosterone were characterised by several hormone pulses. Cabergoline administration caused a minor but significant reduction of the mean prolactin concentration (2.9 AE 0.2 ng ml À1 , p < 0.05) and did not affect the secretion of LH (mean 4.6 AE 1.3 ng ml À1 versus 4.4 AE 1.7 ng ml À1 ) or testosterone (2.5 AE 0.9 ng ml À1 versus 2.4 AE 1.2 ng ml À1 ). Under control conditions, a significant prolactin release was induced by intravenous TRH administration (before TRH: 3.8 AE 0.9 ng ml À1 ,

show abstract

Section: Discussioncontrasting

confidence: 82%

Effects of the dopamine agonist cabergoline on the pulsatile and TRH-induced secretion of prolactin, LH, and testosterone in male beagle dogs

Koch

Hoppen²,

Dieleman

et al. 2006

Theriogenology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The use of certain antiprolactinics during pseudo-lactation decreases the inter-estral interval of the treated bitches [1,8,9]. The use of dopaminergic agonists in anticipation of estrus (less than 7 months after the last heat) is very disappointing [10].…”

Section: Resultsmentioning

confidence: 99%

“…The central dopaminergic effect of antiprolactinics that seems to act favorably during this heat-inducing effect. Their efficacy in the onset of estrus depends on dose, duration of treatment [1,8,9].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Anoestrus Treated with Bromocriptine 2.5 mg (Parlodel®) in Atlas Shepherd Bitch: A Case-Control Study

Slimani¹,

Niar²

2017

J Vet Sci Technol

View full text Add to dashboard Cite

This study reports the clinical, ultrasonographic and endocrinological findings of a bitch treated with bromocriptine (Parlodel ® 2.5 mg Breakable tablet box of 30 tablets) for a heat induction. The dosage adapted for the dog was 1.25 mg per day. A atlas shepherd dog five years old, which had a heat back delay of more than 8 months, was presented to the canine clinical pathology of Tiaret veterinary science institute for consultation. The vaginal smears and ultrasound of the ovaries were combined with the proportioning of progesterone. Vaginal cytology detected a phase of anoestrus. the estimated ovarian volume measured with abdominal ultrasound was 9+/-1.04 mm. The ovaries were of small oval shape with homogeneous echogenicity, similar to that of the renal cortex, with the presence of a few very small, slightly hyperechoic structures on the two ovaries. The progesterone level was 3 nmol/l. No structural anomaly of ovaries and no genital infection were observed on clinical examination.

show abstract

“…14 Bromocriptine inhibits release and synthesis of prolactin by acting directly on the prolactin-secreting cells of the anterior pituitary. 15 In patients with acromegaly, bromocriptine treatment results in reduction of serum growth hormone levels, 16 which consequently blocks the unfavorable effect of growth hormone on the heart. Several studies have found that early heart attack could be effectively controlled after successful treatment of pituitary tumors, 17,18 thus indicating that early-stage cardiovascular complications are reversible.…”

Section: Case Reportmentioning

confidence: 99%

Malignant ventricular tachycardia in acromegaly: a case report

Liu

et al. 2014

Sao Paulo Med. J.

View full text Add to dashboard Cite

CONTEXT: In patients with acromegaly, cardiovascular complications are the main cause of death; sudden death has been associated with ventricular tachyarrhythmias. In other patients with life-threatening malignant ventricular tachyarrhythmias, surgical placement of an implantable cardioverter-defibrillator (ICD) has proved highly effective in reducing sudden death rates. CASE REPORT: The present article reports the case of a 50-year-old male acromegalic patient who presented symptoms of syncope induced by ventricular tachycardia. An ICD was surgically implanted and a pituitary adenoma, which was responsible for the acromegaly, was completely removed in the same procedure. The surgery was successful and the ventricular arrhythmias were effectively terminated. During six months of follow-up, no documented arrhythmic episodes occurred. CONCLUSION: In patients with acromegaly, malignant ventricular tachyarrhythmia might be effectively controlled by implantation of an ICD and surgical removal of the pituitary adenoma. RESUMO CONTEXTO:As complicações cardiovasculares são a principal causa de morte em pacientes com acromegalia, e a morte súbita tem sido associada a taquiarritmias ventriculares. Em outros pacientes com risco de vida por taquiarritmias ventriculares malignas, a aplicação cirúrgica de um cardioversor-desfibrilador implantável (CDI) provou ser altamente eficaz na redução das taxas de morte súbita. RELATO DE CASO: O presente artigo relata o caso de um paciente acromegálico de 50 anos de idade e do sexo masculino, que apresentava sintomas de síncope induzida por taquicardia ventricular. Foi implantado cirurgicamente nesse paciente um CDI e na mesma intervenção cirúrgica foi completamente removido um adenoma hipofisário responsável pela acromegalia. A cirurgia foi bem-sucedida e o paciente deixou de sofrer de arritmias ventriculares. Durante seis meses de acompanhamento, não se documentaram, nesse paciente, episódios arrítmicos. CONCLUSÃO: A taquiarritmia ventricular maligna pode ser efetivamente controlada em pacientes com acromegalia pela implantação de um CDI combinado com a remoção cirúrgica do adenoma hipofisário.

show abstract

Low doses of bromocriptine shorten the interestrous interval in the bitch without lowering plasma prolactin concentration

Cited by 27 publications

References 32 publications

Effects of the dopamine agonist cabergoline on the pulsatile and TRH-induced secretion of prolactin, LH, and testosterone in male beagle dogs

Effects of the dopamine agonist cabergoline on the pulsatile and TRH-induced secretion of prolactin, LH, and testosterone in male beagle dogs

Anoestrus Treated with Bromocriptine 2.5 mg (Parlodel®) in Atlas Shepherd Bitch: A Case-Control Study

Malignant ventricular tachycardia in acromegaly: a case report

Contact Info

Product

Resources

About